Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome) [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing's syndrome), will be presented at the Endocrine Society (ENDO) annual meeting in Boston (June 3) and the Heart in Diabetes (HiD) conference in Philadelphia (June 7). ENDO 2024, Boston Convention & Exhibition Center Late-Breaking Poster Presentation: Open-label Results From GRACE, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of Endogenous Hypercortisolism (Cushing Syndrome) Date & Time: Monday, June 3, 2024 12:00-1:30 pm ET Presenter: Rosario Pivonello, MD, PhD, Principal Investigator of the GRACE study and Professor of Endocrinology at Università Federico II
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions [Yahoo! Finance]Yahoo! Finance
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific SessionsGlobeNewswire
- What Makes Corcept Therapeutics (CORT) a Good Investment Bet? [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock.MarketBeat
- Corcept Therapeutics Stock Merits Accumulation [Seeking Alpha]Seeking Alpha
CORT
Earnings
- 5/1/24 - Beat
CORT
Sec Filings
- 6/24/24 - Form 4
- 6/6/24 - Form 4
- 6/5/24 - Form 4
- CORT's page on the SEC website